ERBITUX
LOE ApproachingmAbcetuximab
BLAINTRAVENOUSVIALPriority Review
Approved
Feb 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
Priority Review
ERBITUX (cetuximab) is her1 antagonists [moa]. First approved in 2004.
Drug data last refreshed 19h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ERBITUX (cetuximab) is a monoclonal antibody that blocks the epidermal growth factor receptor (EGFR/HER1), inhibiting tumor cell growth and proliferation. It is indicated for EGFR-expressing colorectal and head-and-neck cancers, administered intravenously. The drug represents a foundational targeted therapy approach developed over two decades ago.
$7.0MPart D
LOE ApproachingDeclining
Mature asset with modest Medicare utilization; commercial teams are typically lean and focused on retention rather than growth.
Mechanism of Action
HER1 Antagonists
Pharmacologic Class:
Epidermal Growth Factor Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)
Started Oct 2026
600 enrolled
Colorectal Cancer
Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients
Started Oct 2026
267 enrolled
Colorectal Cancer Metastatic
A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal Cancer
Started Oct 2026
27 enrolled
Colorectal CancerAdenocarcinoma of the ColonAdenocarcinoma of the Rectum
A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation
Started Sep 2026
222 enrolled
Advanced Solid Tumors CancerPancreatic Ductal AdenocarcinomaRAS Mutation
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)
Started Aug 2026
960 enrolled
Left-sided Colorectal Cancer
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.